Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450- based cancer gene therapy model

Cancer Gene Therapy

Volumn 7, Issue 7, 2000, Pages 1034-1042

  Huang, Zeqi ^a   Raychowdhury, Malay K ^a   Waxman, David J ^a  

^a Boston University   (United States)

Author keywords

Cyclophosphamide; Methimazole; P450 based cancer gene therapy

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; THIAMAZOLE;

ADOLESCENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; GENE EXPRESSION; GENE THERAPY; HEMATURIA; HYPOTHYROIDISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0033943812     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700200     Document Type: Article

References (55)

1. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther. 1988;37:301-355.
2. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997;17:146S-154S.
3. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 1989;49:2344-2350.
4. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 1993;53:5629-5637.
5. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 1996;24:899-905.
6. Nakajima T, Wang RS, Nimura Y, et al. Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas. Carcinogenesis. 1996;17:1477-1481.
7. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate activity-based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles. Drug Metab Dispos. 1999; 27:655-666.
8. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther. 1994;5:969-978.
9. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995;55:581-589.
10. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16: 444-448.
11. Lohr M, Muller P, Karle P, et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther. 1998;5:1070-1078.
12. Jounaidi Y, Hecht JED, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998;58:4391-4401.
13. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-287.
14. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer. 1997;33:1005-1016.
15. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by co-expression of the P450 reductase gene. Cancer Res. 1997; 57:4830-4837.
16. Waxman DJ, Chen L, Hecht JED, Jounaidi Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab Rev. 1999;31:503-522.
17. Miwa GT, West SB, Lu AYH. Studies on the rate-limiting enzyme component in the microsomal monooxygenase system: incorporation of purified NADPH cytochrome c-reductase and cytochrome P450 into rat liver microsomes. J Biol Chem. 1978;253:1921-1929.
18. Cawley GF, Batie CJ, Backes WL. Substrate-dependent competition of different P450 isozymes for limiting NADPH-cytochrome P450 reductase. Biochemistry. 1995; 34:1244-1247.
19. Cooper DS, Kieffer JD, Saxe V, Mover H, Maloof F, Ridgway EC. Methimazole pharmacology in the rat: studies using a newly developed radioimmunoassay for methimazole. Endocrinology. 1984;114:786-793.
20. Waxman DJ, Morrissey JJ, LeBlanc GA. Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase. Mol Pharmacol. 1989;35: 519-525.
21. Ram PA, Waxman DJ. Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues: regulation by multiple mechanisms. J Biol Chem. 1992;267:3294-3301.
22. Ram PA, Waxman DJ. Pretranslational control by thyroid hormone of rat liver steroid 5 α-reductase and comparison to the thyroid dependence of two growth hormone-regulated CYP2C mRNAs. J Biol Chem. 1990;265:19223-19229.
23. Brain EG, Yu LJ, Gustafsson K, Drewes P, Waxman DJ. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br J Cancer. 1998;77:1768-1776.
24. Yu LJ, Drewes P, Gustafsson K, Brain EGC, Hecht JED, Waxman DJ. In vivo modulation of alternative pathways of P450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther. 1999;288:928-937.
25. Barker M, Hoshino T, Gurcay O, et al. Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1973;33: 976-986.
26. Wallen CA, Michaelson SM, Wheeler KT. Cell survival as a determinant of tumor cure for rat 9L subcutaneous tumors following microwave-induced hyperthermia. Eur J Cancer Clin Oncol. 1982;18:37-44.
27. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392-8396.
28. Hecht JED, Jounaidi Y, Waxman DJ. In: Walther W, Stein U, eds. Methods in Molecular Medicine Series. Gene Therapy of Cancer: Methods and Protocols. Human Press, Inc.; 2000.
29. Chang TKH, Waxman DJ. In: Phillips IR, Shephard EA, eds. Methods in Molecular Biology Series: Cytochrome P450 Protocols, Vol. 107. Humana Press, Inc.; 1998:103-109,.
30. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148-154.
31. Lartigau E, Guichard M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br J Cancer. 1996;73:1480-1485.
32. Chang TK, Waxman DJ. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 α-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res. 1993;53:2490-2497.
33. Chijiiwa K, Linscheer WG, Raheja KL, Cho C. Effects of propylthiouracil on urinary metabolites of cyclophosphamide in rats. Cancer Res. 1983;43:5205-5209.
34. O'Leary KA, Li HC, Ram PA, McQuiddy P, Waxman DJ, Kasper CB. Thyroid regulation of NADPH: cytochrome P450 oxidoreductase: identification of a thyroid-responsive element in the 5′-flank of the oxidoreductase gene. Mol Pharmacol 1997;52:46-53.
35. Arlotto MP, Parkinson A. Identification of cytochrome P450a (P450IIA1) as the principal testosterone 7 α-hydroxylase in rat liver microsomes and its regulation by thyroid hormones. Arch Biochem Biophys. 1989;270:458-471.
36. Ram PA, Waxman DJ. Hepatic P450 expression in hypothyroid rats: differential responsiveness of male-specific P450 forms 2a (IIIA2), 2c (IIC11), and RLM2 (IIA2) to thyroid hormone. Mol Endocrinol. 1991;5:13-20.
37. Peng HM, Coon MJ. Regulation of rabbit cytochrome P450 2E1 expression in HepG2 cells by insulin and thyroid hormone. Mol Pharmacol. 1998;54:740-747.
38. Imaoka S, Nakamura M, Ishizaki T, et al. Regulation of renal cytochrome P450s by thyroid hormone in diabetic rats. Biochem Pharmacol. 1993;46:2197-2200.
39. Webb SJ, Xiao GH, Geoghegan TE, Prough RA. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone. Mol Pharmacol. 1996;49: 276-287.
40. Singleton DW, Lei XD, Webb SJ, Prough RA, Geoghegan TE. Cytochrome P-450 mRNAs are modulated by dehydroepiandrosterone, nafenopin, and triiodothyronine. Drug Metab Dispos. 1999;27:193-200.
41. Andersson U, Yang YZ, Bjorkhem I, Einarsson C, Eggertsen G, Gafvels M. Thyroid hormone suppresses hepatic sterol 12α-hydroxylase (CYP8B1) activity and messenger ribonucleic acid in rat liver: failure to define known thyroid hormone response elements in the gene. Biochim Biophys Acta. 1999;1438:167-174.
42. Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism: deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos. 1996;24:1254-1262.
43. Rahman A, Esmaili A, Saatcioglu F. A unique thyroid hormone response element in the human immunodeficiency virus type 1 long terminal repeat that overlaps the Sp1 binding sites. J Biol Chem. 1995;270:31059-31064.
44. Ross AD, Varghese G, Oporto B, Carmichael FJ, Israel Y. Effect of propylthiouracil treatment on NADPH-cytochrome P450 reductase levels, oxygen consumption, and hydroxyl radical formation in liver microsomes from rats fed ethanol or acetone chronically. Biochem Pharmacol. 1995;49:979-989.
45. Shoemaker JP, Bradley RL, Hoffman RV. Increased survival and inhibition of mammary tumors in hypothyroid mice. J Surg Res. 1976;21:151-154.
46. Mishkin S, Morris HP, Yalovsky MA, Narasimha Murthy PV. Increased survival of rats bearing Morris hepatoma 7800 after induction of hypothyroidism. Cancer Res. 1979; 39:2371-2375.
47. Mishkin SY, Pollack R, Yalovsky MA, Morris HP, Mishkin S. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res. 1981;41:3040-3045.
48. Vail DM, Elfarra AA, Cooley AJ, Panciera DL, MacEwen EG, Soergel SA. Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model. Cancer Chemother Pharmacol. 1993;33:25-30.
49. Braunlich H, Appenroth D, Fleck C. Protective effects of methimazole against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol. 1997;17:41-45.
50. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia: a novel paradigm. In Vivo. 1996;10:245-247.
51. Hercbergs A, Leith JT. Spontaneous remission of metastatic lung cancer following myxedema coma: an apoptosis-related phenomenon? J Natl Cancer Inst. 1993;85:1342-1343.
52. Sorrentino JM, Kirkland WL, Sirbasku DA. Control of cell growth: requirement of thyroid hormones for the in vivo estrogen-dependent growth of rat pituitary tumor cells. J Natl Cancer Inst. 1976;56:1155-1158.
53. Mason RM, Bansal MK. Different growth rates of swarm chondrosarcoma in Lewis and Wistar rats correlate with different thyroid hormone levels. Connect Tissue Res. 1987;16:177-185.
54. Petry TW, Eling TE. The mechanism for the inhibition of prostaglandin H synthase-catalyzed xenobiotic oxidation by methimazole: reaction with free radical oxidation products. J Biol Chem. 1987;262:14112-14118.
55. Weetman AP, Tandon N, Morgan BP. Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet. 1992;340:633-636.